HMO production

By expressing the genetic modification of YberC protein in Yersinia burgdoria in host cells, the HMO production and purification process of human milk oligosaccharides is optimized, and the HMO production efficiency and purification problems in the prior art are solved, achieving efficient and economical HMO manufacturing.

CN114981291BActive Publication Date: 2024-12-06GLYCOM AS
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
CN202180010202.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-01-23
Filing Date
2021-01-22
Publication Date
2024-12-06
Estimated Expiration
2041-01-22

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently produce and purify human milk oligosaccharides (HMO) in host cells, especially because the specific structure of sugar transporter substrate is not fully studied, resulting in unpredictable prediction of transporter function and the inability to accurately determine the appropriate one. Transporters are used for the efflux of HMO structures produced by different recombination.

Method used

Using genetically modified cells expressing the main facilitation factor superfamily (MFS) protein, specifically using YberC protein from Yersinia burgdoria, optimizes the fermentation and purification process of HMO by encoding recombinant nucleic acids similar to specific amino acid sequences, and improves the Total HMO yield and purification efficiency.

Benefits of technology

The amount of HMO produced is significantly increased, the formation of by-products and the formation of biomass is reduced, the recovery and purification process of HMO is simplified, and the efficiency of the manufacturing process and the quality of the product are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114981291B_ABST
    Figure CN114981291B_ABST
Patent Text Reader

Abstract

The inventive concept relates to a genetically modified cell capable of producing oligosaccharides, preferably HMOs, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and a method of producing oligosaccharides, preferably HMOs, using said cell.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of recombinant production of biomolecules in host cells. More specifically, the present invention relates to a method for recombinant production of human milk oligosaccharides (HMOs) using genetically modified cells expressing major facilitator superfamily (MFS) proteins. Background Art

[0002] Human milk oligosaccharides (HMOs) are the third largest solid component in human milk and are highly resistant to enzymatic hydrolysis. Therefore, a large fraction of HMOs is essentially undigested and unabsorbed, which allows them to pass through the colon. In the colon, HMOs can serve as substrates to shape the intestinal ecosystem by selectively stimulating the growth of specific saccharolytic bacteria. This selectivity is seen as beneficial for both infants and adults, as Bifidobacterium strains are thought to have a positive impact on intestinal health (Chichlowski M. et al., (2012) J. Pediatr. Gastroenterol. Nutr. 5: 251-258; Elison E. et al., (2016) Brit J. Nurt, 116: 1356-1368).

[0003] In addition to their prebiotic properties, HMOs are also associated with other positive effects, which expand their field of application (Kunz C. et al., (2014) Food Oligosaccharides: Production, Analysis and Bioactivity, 1st edition, pp. 5-20, editors: Moreno J. and Luz Sanz M., John Wiley & Sons, Ltd).

[0004] The apparent health benefits of HMOs have led to their approval for use in foods, such as infant formula and food, as well as consumer healthcare products. Biotechnological production of HMOs is a valuable, cost-effective way to manufacture HMOs on a large scale. It relies on the construction of genetically engineered bacteria to express the glycosyltransferases required to synthesize the desired oligosaccharides and to utilize the bacterial intrinsic nucleotide sugar pool as HMO precursors. Recent developments in the biotechnological production of HMOs have made it possible to overcome certain inherent limitations of bacterial expression systems. For example, HMO-producing bacterial cells can be genetically modified to increase the limited intracellular nucleotide sugar pool in bacteria (WO2012112777), to increase the activity of enzymes involved in HMO production (WO2016040531), or to promote the secretion of synthesized HMOs into the extracellular medium (WO2010142305, WO2017042382). In addition, the expression of the target gene in the recombinant cell can be regulated by using specific promoters or other gene expression regulatory factors, such as those recently described in WO2019123324.

[0005] An advantage of the method described in WO2010142305 and WO2017042382 is that it allows for a reduction in the metabolic burden on the producing cells through high levels of recombinant gene expression, for example using the methods of WO2012112777, WO2016040531 or WO2019123324. This approach has attracted increasing attention in the engineering of recombinant HMO producing cells, for example, several new sugar transporter encoding genes and fermentation procedures have recently been described that can facilitate the efflux of recombinantly produced 2'-fucosyllactose (2'-FL), which is the most abundant HMO in human milk (WO2018077892, US201900323053, US201900323052). However, currently, no algorithm can accurately identify the correct transporter for efflux of different recombinantly generated HMO structures among the numerous bacterial proteins with predicted transporter functions in multiple protein databases (e.g., UniProt). Summary of the invention

[0006] The development of efficient sugar efflux transporters for recombinantly produced HMOs and recombinant cells expressing the same would facilitate large-scale industrial HMO manufacturing.

[0007] The present invention provides a recombinant cell capable of producing human milk oligosaccharides (HMOs), wherein the cell expresses a heterologous gene encoding a putative MFS (major facilitator superfamily) transporter derived from the bacterium Yersinia bercovieri. More specifically, the present invention relates to a genetically modified cell optimized for the production of oligosaccharides, in particular HMOs, comprising a recombinant nucleic acid encoding a protein having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1 ( Figure 4 ). The amino acid sequence identified herein as SEQ ID NO: 1 is an amino acid sequence that has 100% identity to the amino acid sequence having GenBank Accession No. EEQ08298.1 (https: / / www.ncbi.nlm.nih.gov / protein / EEQ08298.1 / ). The MFS transporter having the amino acid sequence of SEQ ID NO: 1 is interchangeably identified herein as "YberC protein" or "YberC transporter" or "YberC"; the nucleic acid sequence encoding the YberC protein is identified herein as "YberC encoding nucleic acid / DNA" or "yberC gene" or "yberC".

[0008] The present invention demonstrates that the use of HMO-producing recombinant cells expressing the YberC protein can significantly improve the HMO production process in terms of fermentation and purification of the HMO. The recombinant cells and methods for HMO production disclosed herein provide higher overall yields of HMO produced, lower by-product formation or by-product to product ratios, lower biomass formation per fermentation, and facilitate recovery of HMO during downstream processing of the fermentation broth.

[0009] Surprisingly, it was found that the expression of the DNA sequence encoding YberC in different HMO producing cells was associated with the accumulation of some specific HMOs in the extracellular medium and some other HMOs inside the producing cells as well as an increase in the total HMO production. Surprisingly, it was found that the increased efflux of the produced HMOs was characteristic of HMOs consisting of three or four units of monosaccharides, i.e., the HMOs were trisaccharides and tetrasaccharides, such as 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose 2 (LNT-2), lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), but not for larger oligosaccharide structures, such as pentasaccharides and hexasaccharides, which accumulated inside the producing cells. Surprisingly, it was also found that, especially in HMOs in the corresponding HMO producing cells expressing yberC, the total production of lacto-N-triose 2 (LNT-2), lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) was increased, while correspondingly, the production of byproducts in these cells, such as p-lacto-N-neohexaose (pLNnH) or p-lacto-neohexaose II (pLNH-II) was generally reduced, and the byproduct oligosaccharides were generally accumulated inside the producing cells. In addition, unexpectedly, the expression of the YberC protein in the HMO producing cells resulted in reduced biomass formation during high cell density fermentations and resulted in healthier cell cultures, as reflected by the reduced number of dead cells at the end of the fermentation, which makes the manufacturing process more efficient because more product is produced per biomass unit.

[0010] Thus, a first aspect of the present invention relates to a genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs) selected from the group consisting of 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose IV (LNFP IV) and lacto-N-fucopentaose V (LNFP V), p-lacto-N-neohexaose (pLNnH) and p-lacto-neohexaose II (pLNH-II), wherein the cell comprises a recombinant nucleic acid encoding a protein of SEQ ID NO: 1 or a functional homologue thereof, the functional homologue having the same identity as SEQ ID NO: 1. NO:1 has at least 80% identity, preferably at least 85% identity, more preferably at least 90% identity of the amino acid sequence. In particular, the present invention relates to the genetically modified cell capable of producing one or more human milk oligosaccharides (HMO), wherein the oligosaccharide is selected from lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose IV (LNFP IV), lacto-N-fucopentaose V (LNFP V), p-lacto-N-neohexaose (pLNnH) and p-lacto-neohexaose II (pLNH-II).

[0011] A second aspect of the present invention relates to a nucleic acid construct comprising a nucleic acid sequence encoding an MFS transporter protein, wherein the nucleic acid sequence encoding the protein has at least 70% sequence identity with SEQ ID NO: 2, such as at least 80%, such as at least 85%, such as at least 95%, such as at least 99%, and a genetically modified cell comprising the nucleic acid construct, which is Escherichia coli.

[0012] In one aspect, the nucleic acid construct comprises a nucleic acid sequence encoding an MFS transporter, wherein the nucleic acid sequence is at least 70% identical to SEQ ID NO:2.

[0013] A third aspect of the invention relates to a method for producing one or more oligosaccharides, the method comprising the steps of:

[0014] (i) providing a genetically modified cell capable of producing HMO, wherein the cell comprises a recombinant nucleic acid encoding a protein of SEQ ID NO: 1 or a functional homologue thereof having an amino acid sequence that is at least 80% identical, preferably at least 85% identical, more preferably at least 90% identical to SEQ ID NO: 1;

[0015] (ii) culturing the cell according to (i) in a suitable cell culture medium to express the recombinant nucleic acid;

[0016] (iii) harvesting the one or more HMOs produced in step (ii).

[0017] The present invention also relates to the use of a genetically modified cell or a nucleic acid construct comprising a heterologous nucleic acid sequence encoding a major facilitator superfamily (MFS) protein for producing one or more human milk oligosaccharides (HMOs), wherein the nucleic acid sequence has at least 70% sequence identity to SEQ ID NO: 2, and the human milk oligosaccharides are selected from 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose IV (LNFP IV) and lacto-N-fucopentaose V (LNFP V), p-lacto-N-neohexaose (pLNnH) and p-lacto-neohexaose II (pLNH-II), in particular selected from lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose IV (LNFP IV) and lacto-N-fucopentaose V (LNFP V), p-lacto-N-neohexaose (pLNnH) and p-lacto-neohexaose II (pLNH-II).

[0018] As described above, during the cultivation of genetically modified cells capable of producing one or more HMOs, these cells contain a nucleic acid encoding a YberC transporter, surprisingly, it was found that the corresponding one or more HMOs were produced in high yields, while the formation of byproducts and biomass was reduced. This is beneficial for the recovery of HMOs in downstream processes, for example, the overall recovery and purification procedures can contain fewer steps, and the total time for purification can be shortened, so that the recovery of the product is more labor-saving and cost-effective.

[0019] These effects of increasing product yield and facilitating product recovery make the present invention superior to prior art disclosures.

[0020] Further aspects and advantageous features of the invention are described in detail below and are illustrated by means of non-limiting working examples. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The percentages (%) of strains with the best expression of glycosyltransferase genes, differing only in the expression of the heterologous transporter gene yberC0001_9420, relative to the LNT-2 concentration in total, supernatant and pellet samples are shown. In contrast to strain MP3941, strain MP3940 expresses the yberC0001_9420 gene.

[0022] Figure 2 The percentages (%) of relative LNnT and byproduct concentrations in total, supernatant and pellet samples are shown for strains MP4436 and MP3863. While both strains showed optimal expression of the desired glycosyltransferase genes, MP3863 expressed the heterologous transporter gene yberC0001_9420 under the control of the Plac element.

[0023] Figure 3 The relative LNT and byproduct concentrations in total, supernatant and precipitate samples are shown as percentages (%) for strains MP4473, MP4462 and MP4547. Although all three strains showed optimal expression of the desired genes, only MP4462 and MP4547 expressed the heterologous transporter gene yberC0001_9420 under the control of the Plac or PglpF elements, respectively.

[0024] Figure 4 SEQ ID NO: 1 is shown. DETAILED DESCRIPTION

[0025] Hereinafter, the embodiments of the present invention will be described in further detail. Unless otherwise explicitly stated, each specific variation of a feature can be applied to other embodiments of the present invention.

[0026] In general, unless explicitly defined or otherwise stated, all terms used herein should be interpreted according to their ordinary meaning in the technical field and apply to all aspects and embodiments of the present invention. Unless explicitly stated otherwise, all references to "a / an / the" [cell, sequence, gene, transporter, step, etc.] should be openly interpreted as referring to at least one example of the cell, sequence, gene, transporter, step, etc. Unless explicitly stated, the steps of any method disclosed herein do not have to be performed in the exact order disclosed.

[0027] The present invention generally relates to genetically modified cells for the efficient production of oligosaccharides and the use of said genetically modified cells in methods for producing oligosaccharides. In particular, the present invention relates to genetically modified cells capable of synthesizing oligosaccharides, preferably heterologous oligosaccharides, especially human milk oligosaccharides (HMOs). Therefore, the cells of the present invention are modified to express a set of recombinant nucleic acids necessary for the cell to synthesize one or more HMOs (which enables the cell to synthesize one or more HMOs), such as genes encoding one or more enzymes having the following glycosyltransferase activity. The oligosaccharide-producing recombinant cells of the present invention are further modified to contain a heterologous recombinant nucleic acid sequence, preferably a DNA sequence, which encodes an MFS (major facilitator superfamily) protein derived from Yersinia burnetii. More specifically, the present invention relates to genetically modified cells optimized for the production of one or more specific oligosaccharides, in particular one or more specific HMOs, comprising a recombinant nucleic acid encoding a polypeptide corresponding to SEQ ID NO: 1 ( Figure 4 ) has at least 80% sequence similarity, preferably at least 85%, more preferably at least 90%, and even more preferably at least 95% sequence similarity to the amino acid sequence of Figure 4 ). The amino acid sequence identified herein as SEQ ID NO: 1 is an amino acid sequence having 100% identity with the amino acid sequence having GenBank Accession No.: EEQ08298.1 (https: / / www.ncbi.nlm.nih.gov / protein / EEQ08298.1 / ).

[0028] Thus, a first aspect of the present invention relates to a genetically modified cell capable of producing one or more HMOs, wherein the cell comprises a recombinant nucleic acid encoding the protein of SEQ ID NO: 1 or a functional homologue thereof having an amino acid sequence that is at least 80% identical, preferably at least 85% identical, preferably at least 90% identical to SEQ ID NO: 1.

[0029] The MFS transporter having the amino acid sequence of SEQ ID NO: 1 is identified interchangeably herein as “YberC protein” or “YberC transporter” or “YberC”; the nucleic acid sequence encoding the YberC protein is identified herein as “YberC encoding nucleic acid / DNA” or “yberC gene” or “yberC”.

[0030] The term "major facilitator superfamily (MFS)" refers to a large and unusually diverse family of secondary active transporters responsible for transporting a range of different substrates, including sugars, drugs, hydrophobic molecules, peptides, organic ions, etc. The specificity of sugar transporters is highly unpredictable, and the identification of novel transporters with specificity for, for example, oligosaccharides requires unburdened laboratory experiments (for more details, see the review by Reddy VS et al., (2012), FEBS J. 279(11): 2022-2035). The term "MFS transporter" in this context refers to a protein that facilitates the transport of oligosaccharides, preferably HMOs, across cell membranes, preferably HMOs / oligosaccharides synthesized by the host cell from the cytosol to the outside of the cell, preferably HMOs / oligosaccharides comprising three or four sugar units, in particular LNT-2, LNT, LNnT, 3'-SL or 6'-SL. In addition, or alternatively, MFS transporters may also facilitate the efflux of molecules that are not considered HMOs or oligosaccharides according to the present invention, such as lactose, glucose, cellular metabolites or toxins.

[0031] In the context of two or more nucleic acid or amino acid sequences, the term "[certain] sequence identity %" refers to that when compared and aligned to achieve maximum correspondence on a comparison window or a specified nucleic acid or amino acid sequence, two or more sequences have the same nucleotides or amino acid residues within a given percentage (i.e., the sequences have at least 90% identity). The identity percentage of nucleic acid or amino acid sequences can be measured using the BLAST 2.0 sequence comparison algorithm with default parameters, or by manual alignment and visual inspection (e.g., http: / / www.ncbi.nlm.nih.gov / BLAST / ). This definition also applies to the complement of the test sequence and sequences with deletions and / or additions, as well as sequences with replacements. An example of an algorithm suitable for determining identity percentage, sequence similarity and alignment is the BLAST 2.2.20 algorithm, which is described in Altschul et al., Nucl.Acids Res 25, 3389 (1997). BLAST 2.2.20 is used to determine the sequence identity percentages of nucleic acids and proteins of the present invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ). Examples of sequence alignment algorithms are CLUSTAL Omega (http: / / www.ebi.ac.uk / Tools / msa / clustalo / ), EMBOSS Needle (http: / / www.ebi.ac.uk / Tools / psa / emboss_needle / ), MAFFT (http: / / mafft.cbrc.jp / alignment / server / ), or MUSCLE (http: / / www.ebi.ac.uk / Tools / msa / muscle / ).

[0032] In the present invention, the term "oligosaccharide" refers to a sugar polymer containing multiple monosaccharide units. In some embodiments, the preferred oligosaccharide is a sugar polymer composed of three or four monosaccharide units (ie, trisaccharides or tetrasaccharides). The preferred oligosaccharide of the present invention is human milk oligosaccharide (HMO).

[0033] The term "human milk oligosaccharide" or "HMO" herein refers to a complex carbohydrate found in human milk (for reference, see Urashima et al.: Milk Oligosaccharides. Nova Science Publisher (2011); or Chen, Adv. Carbohydr. Chem. Biochem. 72, 113 (2015)). HMO has a core structure comprising a lactose unit at the reducing end, which lactose unit may be elongated by one or more β-N-acetyl-lactosamine units and / or one or more β-lacto-N-disaccharide units, and the core structure may be partially substituted by α-L-fucopyranyl and / or α-N-acetyl-neuraminic acid (sialic acid). In this regard, non-acidic (or neutral) HMOs do not contain sialic acid residues, and acidic HMOs have at least one sialic acid residue in their structure. Non-acidic (or neutral) HMOs may be fucosylated or non-fucosylated. Examples of such neutral non-fucosylated HMOs include lacto-N-triose 2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-neohexose (LNnH), p-lacto-N-neohexose (pLNnH), p-lacto-N-hexaose (pLNH), and lacto-N-hexaose (LNH). Examples of neutral fucosylated HMOs include 2'-fucosyllactose (2'-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-difucohexaose I (LNDFH-I), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose II (LNFP-II), lacto-N-fucopentaose III (LNFP-III), lacto-N-difucohexaose LNDFH-III, fucosyl-lacto-N-hexaose II (FLNH-II), lacto-N-fucopentaose V (LNFP-V), lacto-N-difucohexaose II (LNDFH-II), fucosyl-lacto-N-hexaose I (FLNH-I), fucosyl-p-lacto-N-hexaose I (FpLNH-I), fucosyl-p-lacto-N-neohexaose II (F-pLNnH II), and fucosyl-lacto-N-neohexaose (FLNnH).Examples of acidic HMOs include 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), 3-fucosyl-3'-sialyllactose (FSL), 3'-O-sialyllacto-N-tetraose a (LST a), fucosyl-LST a (FLST a), 6'-O-sialyllacto-N-tetraose b (LST b), fucosyl-LST b (FLST b), 6'-O-sialyllacto-N-neotetraose (LST c), fucosyl-LST c (FLST c), 3'-O-sialyllacto-N-neotetraose (LST d), fucosyl-LST d (FLST d). d), sialyl-lacto-N-hexaose (SLNH), sialyl-lacto-N-neohexaose I (SLNH-I), sialyl-lacto-N-neohexaose II (SLNH-II) and disialyl-lacto-N-tetraose (DSLNT). In the context of the present invention, lactose is not considered an HMO.

[0034] In some embodiments of the invention, tri-HMOs and tetra-HMOs may be preferred, such as the trisaccharides LNT-2, 3'-SL, 6'-SL and the tetrasaccharides LNT, LNnT, FSL.

[0035] In order to be able to synthesize one or more HMOs, the recombinant cells of the present invention contain at least one recombinant nucleic acid encoding a functional enzyme with glycosyltransferase activity. The galactosyltransferase gene can be integrated into the genome of the host cell (via chromosomal integration), or it can be contained in plasmid DNA and expressed by the plasmid. If two or more glycosyltransferases are required for the production of HMOs, such as LNT or LNnT, two or more recombinant nucleic acids encoding different enzymes with glycosyltransferase activity can be integrated into the genome and / or expressed from a plasmid, for example, β-1,3-N-acetylglucosaminyltransferase (a first recombinant nucleic acid encoding a first glycosyltransferase) for the production of LNT is combined with β-1,3-galactosyltransferase (a second recombinant nucleic acid encoding a second glycosyltransferase), wherein the first and second recombinant nucleic acids can be chromosomally integrated or integrated on a plasmid independently of each other. In a preferred embodiment, both the first and second recombinant nucleic acids are stably integrated into the chromosome of the producing cell; in another embodiment, at least one of the first and second glycosyltransferases is carried by a plasmid. The protein / enzyme having glycosyltransferase activity (glycosyltransferase) can be selected in different embodiments from enzymes having α-1,2-fucosyltransferase, α-1,3-fucosyltransferase, α-1,3 / 4-fucosyltransferase, α-1,4-fucosyltransferase, α-2,3-sialyltransferase, α-2,6-sialyltransferase, β-1,3-N-acetylglucosaminyltransferase, β-1,6-N-acetylglucosaminyltransferase, β-1,3-galactosyltransferase and β-1,4-galactosyltransferase activities. For example, the production of LNT requires the modified cells to express at least two glycosyltransferases, namely β-1,3-N-acetylglucosaminyltransferase and β-1,3-galactosyltransferase; the production of LNnT requires the modified cells to express active β-1,3-N-acetylglucosaminyltransferase and active β-1,4-galactosyltransferase; in order to produce 6'-SL, the modified cells must express active α-2,6-sialyltransferase. Some non-limiting embodiments of proteins having glycosyltransferase activity that can be encoded by recombinant genes contained in the production cells can be selected from the non-limiting examples in Table 1.

[0036] Table 1

[0037]

[0038]

[0039]

[0040] One aspect of the present invention is to provide a nucleic acid construct comprising a heterologous nucleic acid sequence encoding a protein capable of sugar transport, the protein being a major facilitator superfamily (MFS) protein as shown in SEQ ID NO:1, or a functional homolog thereof, the amino acid sequence of which is at least 80% identical to SEQ ID NO:1, wherein the nucleic acid sequence encoding the MFS protein has at least 70% sequence identity to SEQ ID NO:2.

[0041] The term "heterologous nucleic acid sequence", "recombinant gene / nucleic acid / DNA coding" or "coding nucleic acid sequence" refers to an artificial nucleic acid sequence (i.e., a nucleic acid sequence produced in vitro using standard laboratory methods for preparing nucleic acid sequences) that includes a set of continuous, non-overlapping triplets (codons) that are transcribed into mRNA and translated into a polypeptide when placed under the control of appropriate control sequences (i.e., promoters). The boundaries of the coding sequence are usually determined by the ribosome binding site, translation start codon (AUG, GUG or UUG) and translation stop codon (UAA, UGA or UAG) located upstream of the open reading frame at the 5' end of the mRNA. Coding sequences may include, but are not limited to, genomic DNA, cDNA, synthetic and recombinant nucleic acid sequences. The term "nucleic acid" includes RNA, DNA and cDNA molecules. It is well known that due to the degeneracy of the genetic code, multiple nucleotide sequences encoding a given protein can be generated. The term nucleic acid can be used interchangeably with the term "polynucleotide". An "oligonucleotide" is a short-chain nucleic acid molecule. A "primer" is an oligonucleotide, whether naturally occurring in a purified restriction endonuclease digest or synthetically produced, that is capable of serving as a starting point for synthesis when placed under conditions that induce synthesis of primer extension products complementary to a nucleic acid strand (i.e., in the presence of nucleotides and an inducing agent, such as a DNA polymerase, at an appropriate temperature and pH). Primers are preferably single-stranded for maximum amplification efficiency, but may be double-stranded. If double-stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is a deoxyribonucleic acid. The primer must be long enough to initiate the synthesis of extension products in the presence of an inducing agent. The exact length of the primer depends on many factors, including temperature, primer source, and method used.

[0042] The recombinant nucleic acid sequence of the present invention can be a coding DNA sequence, such as a gene, or a non-coding DNA sequence, such as a regulatory DNA, such as a promoter sequence. One aspect of the present invention relates to providing a recombinant cell comprising a recombinant DNA sequence encoding one or more enzymes required for HMO production and a DNA sequence encoding a YberC transporter. Therefore, in one embodiment, the present invention relates to a nucleic acid construct comprising a coding nucleic acid sequence, i.e., a recombinant DNA sequence of a target gene, such as a glycosyltransferase gene or a yberC gene, and a non-coding DNA sequence, such as a promoter DNA sequence, such as a recombinant promoter sequence derived from a promoter of a lac operon or a glp operon, or a promoter sequence derived from another genomic promoter DNA sequence, or a synthetic promoter sequence, wherein the coding sequence and the promoter sequence are operably linked. The term "operably linked" refers to a functional relationship between two or more nucleic acid (e.g., DNA) fragments. Generally, it refers to a functional relationship between a transcriptional regulatory sequence and a transcriptional sequence. For example, if the promoter sequence stimulates or regulates the transcription of the coding sequence in an appropriate host cell or other expression system, the promoter sequence is operably linked to the coding sequence. Typically, promoter transcriptional regulatory sequences that are operably linked to a transcribed sequence are physically adjacent to the transcribed sequence, ie, they are cis-acting.

[0043] In one embodiment, the nucleic acid construct of the invention may be part of a vector DNA, in another embodiment, the construct is an expression cassette / cassette integrated into the host cell genome. Thus, the term "nucleic acid construct" refers to an artificially constructed nucleic acid fragment, in particular a DNA fragment, which is intended to be "transplanted" into a target cell (e.g. a bacterial cell) to modify the expression of a gene or to express a gene / coding DNA sequence that may be included in the construct. In the context of the present invention, a nucleic acid construct contains a recombinant DNA sequence comprising two or more recombinant DNA sequences: essentially, a non-coding DNA sequence comprising a promoter DNA sequence and a coding DNA sequence encoding a protein of interest, such as a YberC protein, a glycosyltransferase or another protein that can be used to produce HMOs in a host cell. Preferably, the construct comprises further non-coding DNA sequences that regulate the transcription or translation of the coding DNA of the construct, such as a DNA sequence that promotes ribosome binding to the transcript, a leader DNA sequence that stabilizes the transcript, or a transcription termination sequence.

[0044] The target recombinant nucleic acid contained in the construct (expression cassette) can be integrated into the bacterial genome by conventional methods, for example, by using a linear cassette containing flanking sequences homologous to specific sites on the chromosome, such as the described attTn7 site (Waddell CS and Craig NL, (1988) Feb; 2(2): 137-49.); a method for genomic integration of nucleic acid sequences, wherein the recombination is mediated by the Red recombinase function of phage λ or the RecE / RecT recombinase function of the Rac prophage (Murphy, J Bacteriol. (1998); 180(8): 2063-7; Zhang et al., Nature Genetics (1998) 20: 123-128 Muyrers et al., EMBO Rep. (2000) 1(3): 239-243); a method based on Red / ET recombination (Wenzel et al., ChemBiol. (2005), 12(3): 349-56; Vetcher et al., Appl Environ Microbiol. (2005); 71(4): 1829-35); or positive clones, ie clones carrying the expression cassette, can be selected, for example, by loss or gain of marker gene or gene function.

[0045] According to the present invention, a single copy of the expression cassette comprising the gene of interest is sufficient to ensure the production of the desired HMO and achieve the desired effect. Thus, in some preferred embodiments, the present invention relates to recombinant HMO producing cells comprising one, two or three copies of the gene of interest integrated into the genomic DNA of the cell. In some embodiments, a single copy of the gene is preferred.

[0046] In a preferred embodiment, the recombinant encoding nucleic acid sequence of the nucleic acid construct of the present invention is heterologous with respect to the promoter, which means that it is transcribed under the control of another promoter sequence (i.e., not the promoter sequence of the construct) in the equivalent natural coding sequence in the genome of the species of origin. However, with respect to the host cell, the encoding DNA can be heterologous (i.e., derived from another biological species or genus), such as a DNA sequence encoding a YberC protein expressed in an E. coli host cell, or homologous (i.e., derived from a host cell), such as genes of the colic acid operon, GMAB genes.

[0047] The term "regulatory element" or "promoter" or "promoter region" or "promoter element" is a nucleic acid sequence that is recognized and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Promoters and other transcriptional and translational regulatory nucleic acid sequences (also referred to as "control sequences") are necessary for the expression of a given gene or group of genes (operon). In general, transcriptional and translational regulatory sequences include, but are not limited to, promoter sequences, ribosome binding sites, transcriptional start and stop sequences, translational start and stop sequences, and transcriptional enhancers or activator sequences. "Transcription start site" refers to the first transcribed nucleotide, designated as +1. The nucleotides downstream of the start site are numbered +2, +3, +4, etc., and the nucleotides in the 5' opposite (upstream) direction are numbered -1, -2, -3, etc. The promoter DNA sequence of the construct can be from the promoter region of any gene in the genome of the selected species, preferably the promoter region of the Escherichia coli genomic DNA. Therefore, any promoter DNA sequence that can bind to RNA polymerase and initiate transcription is suitable for implementing the present invention. In principle, any promoter DNA sequence can be used to control the transcription of the target recombinant nucleic acid of the construct, and different or identical promoter sequences can be used to drive the transcription of different target genes integrated in the host cell genome or expression vector DNA. In order to obtain optimal expression of the recombinant gene contained in the construct, the construct may include further regulatory sequences, such as a leading DNA sequence, such as a DNA sequence derived from the 5'-untranslated region (5'UTR) of the Escherichia coli glp gene, a sequence for ribosome binding. Examples of the latter sequences are described in WO2019123324 (incorporated herein for reference) and are illustrated in the non-limiting working examples herein.

[0048] In some preferred embodiments, the regulatory element used to regulate the expression of the recombinant gene included in the construct of the present invention is the glpFKX operator promoter PglpF, and in other preferred embodiments, the promoter is the lac operator promoter Plac.

[0049] On the other hand, the regulatory element used to regulate the expression of the recombinant gene included in the construct of the present invention is mglBAC; galactose / methylgalactoside transporter promoter PmglB or its variants, such as but not limited to PmglB_70UTR of SEQ ID NO:15 or PmglB_70UTR_SD4 of SEQ ID NO:16.

[0050] In another aspect, the regulatory element for regulating the expression of the recombinant gene included in the construct of the present invention is gatYZABCD; tagatose-1,6-bisP aldolase promoter PgatY or a variant thereof, such as but not limited to PgatY_U70UTR of SEQ ID NO: 17.

[0051] Preferred regulatory elements present in the genetically modified cells and / or nucleic acid constructs of the present invention are selected from: PgatY_70UTR, PglpF, PglpF_SD1, PglpF_SD10, PglpF_SD2, PglpF_SD3, PglpF_SD4, PglpF_SD5, PglpF_SD6, PglpF_SD7, PglpF_SD8, PglpF_SD9, Plac_16UTR, Plac, PmglB_70UTR and PmglB_70UTR_SD4.

[0052] Particularly preferred regulatory elements present in the genetically modified cells and / or nucleic acid constructs of the invention are selected from the group consisting of PglpF and Plac.

[0053] In some preferred embodiments, the regulatory element used to regulate the expression of the recombinant gene included in the construct of the present invention is the glpFKX operon promoter PglpF, in other preferred embodiments, the promoter is the lac operon promoter Plac. However, any promoter capable of transcribing and / or regulating the transcription level of one or more recombinant nucleic acids encoding one or more proteins (or one or more regulatory nucleic acids) and allowing the desired effects according to the present invention to be achieved is suitable for implementing the present invention, these proteins (or one or more regulatory nucleic acids) are necessary or beneficial for achieving optimal biosynthetic product levels of one or more HMOs in the host cell, such as glucosyltransferases, proteins involved in the transmembrane transport of HMOs or HMO precursors, gene expression regulatory proteins, etc.

[0054] Preferably, expression of a construct of the invention comprising genes associated with HMO biosynthetic production, a promoter DNA sequence and other regulatory sequences, such as a ribosome binding site sequence (e.g., a Shine-Dalgarno sequence) in a host cell is capable of producing HMO at a level of at least 0.03 g / OD (optical density), e.g., at a level of about 0.05 g / l / OD, about 0.1 g / l / OD or more in 1 liter of fermentation medium comprising a suspension of host cells. For purposes of the present invention, the latter level of HMO production is considered "sufficient" or "optimal," and a host cell capable of producing this level of the desired HMO is considered a "suitable host cell," i.e., the cell can be further modified to express an HMO transporter, such as YberC, to achieve at least one of the effects described herein that are favorable to HMO production.

[0055] The genetically modified cells (host cells or recombinant cells) can be, for example, bacteria or yeast cells. In a preferred embodiment, the genetically modified cells are bacterial cells. Regarding bacterial host cells, there are no restrictions in principle; they can be true bacteria (Gram-positive or Gram-negative) or archaea, as long as they allow genetic manipulation of the target gene to be inserted and can be cultured on a manufacturing scale. Preferably, the host cell has characteristics that allow high cell density culture. Non-limiting examples of bacterial host cells suitable for recombinant industrial production of HMOs according to the present invention can be Erwinia herbicola (Pantoea agglomerans), Citrobacter freundii, Pantoea citrea, Pectobacterium carotovorum or Xanthomonas campestris. Bacillus bacteria, including Bacillus subtilis, Bacillus licheniformis, Bacillus coagulans, Bacillus thermophilus, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, and Bacillus circulans, may also be used.Similarly, bacteria of the genera Lactobacillus and Lactococcus can be modified using the methods of the invention, including, but not limited to, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus jensenii, and Lactococcus lactis. Streptococcus thermophiles and Proprionibacterium freudenreichii are also suitable bacterial species for the invention described herein. Also included as part of the present invention are Enterococcus spp. (e.g., Enterococcus faecium and Enterococcus thermophiles), Bifidobacterium (e.g., Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum), Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas spp. (e.g., Pseudomonas fluorescens and Pseudomonas aeruginosa).The bacteria comprising the characteristics described herein are cultured in the presence of lactose and the oligosaccharides, such as HMOs, produced by the cells are extracted from the bacteria themselves or from the bacterial culture supernatant. In a preferred embodiment, the genetically modified cells of the present invention are E. coli cells.

[0056] In another preferred embodiment, the host cell is a yeast cell, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Kluveromyces lactis, Kluveromyces marxianus, and the like.

[0057] The HMO produced by the recombinant cells of the present invention can be purified using appropriate procedures available in the art (for example, as described in WO2015188834, WO2017182965 or WO2017152918).

[0058] The genetically modified cells of the present invention can be provided using standard methods in the art, such as those described in the manuals of Sambrook et al., Wilson & Walker, Maniatise et al., and Ausubel et al.

[0059] Host cells suitable for HMO production, such as E. coli, may contain an endogenous β-galactosidase gene or an exogenous β-galactosidase gene, for example, E. coli contains an endogenous lacZ gene (e.g., GenBank Accession No. V00296 (GI:41901)). For the purposes of the present invention, the HMO producing cells are genetically manipulated to contain any β-galactosidase gene or an inactivated variant of the gene. The gene may be inactivated by complete or partial deletion of the corresponding nucleic acid sequence from the bacterial genome, or the gene sequence may be mutated in such a way that it is transcribed, or, if transcribed, the transcript is not translated, or, if translated into a protein (i.e., β-galactosidase), the protein does not have the corresponding enzymatic activity. In this way, the HMO producing cells accumulate an increased intracellular lactose pool, which is beneficial for the production of HMOs.

[0060] In some embodiments, the cells produced comprise defective sialic acid decomposition pathways. "Sialic acid decomposition pathways" refers to a series of reactions, usually controlled and catalyzed by enzymes, resulting in sialic acid degradation. Exemplary sialic acid decomposition pathways described herein are Escherichia coli pathways. In this pathway, sialic acid (Neu5Ac; N-acetylneuraminic acid) is degraded by NanA (N-acetylneuraminic acid lyase) and NanK (N-acetylmannosamine kinase) and NanE (N-acetylmannosamine-6-phosphate epimerase), all of which are encoded by the nanATEK-yhcH operon and inhibited by NanR (http: / / ecocyc.org / ECOLI). By introducing mutations in endogenous nanA (N-acetylneuraminic acid lyase) (e.g., GenBank accession number D00067.1 (GL216588)) and / or nanK (N-acetylmannosamine kinase) genes (e.g., GenBank accession number (amino acid) BAE77265.1 (GL85676015)) and / or nanE (N-acetylmannosamine-6-phosphate differential enzyme, GI:947745, incorporated herein by reference), defective sialic acid decomposition pathways are presented in E. coli hosts. Optionally, the nanT (N-acetylneuraminic acid transporter) gene is also inactivated or mutated. Other intermediates of sialic acid metabolism include: (ManNAc-6-P) N-acetylmannosamine-6-phosphate; (GlcNAc-6-P) N-acetylglucosamine-6-phosphate; (GlcN-6-P) glucosamine-6-phosphate and (Fruc-6-P) fructose-6-phosphate. In some preferred embodiments, nanA is mutated. In other preferred embodiments, nanA and nanK are mutated, while nanE remains functional. In another preferred embodiment, nanA and nanE are mutated, while nanK is not mutated, inactivated or deleted. Mutation is one or more changes in the nucleic acid sequence encoding nanA, nanK, nanE and / or nanT gene products. For example, mutation may be 1, 2, at most 5, at most 10, at most 25, at most 50 or at most 100 mutations in the nucleic acid sequence. For example, nanA, nanK, nanE and / or nanT genes are mutated by null mutations. Null mutations as described herein include amino acid substitutions, additions, deletions or insertions, which either result in loss of enzyme function (i.e., reduced activity or inactivity) or result in loss of enzyme (i.e., no gene product). "Deletion" refers to the complete or partial deletion of a coding region, thereby not producing a (functional) gene product. Inactivation refers to a coding sequence that has been altered so that the gene product produced is functionally inactive, or the encoded gene product activity is less than 100%, such as 90%, 80%, 70%, 60%, 50%, 40%, 30% or 20% of the activity of a natural, naturally occurring or endogenous gene product.A "non-mutated" gene or protein does not differ from the native, naturally occurring or endogenous coding sequence or from the corresponding encoded amino acid sequence by 1, 2, at most 5, at most 10, at most 20, at most 50, at most 100, at most 200, or at most 500 or more codons.

[0061] In addition, the host cell (eg, E. coli) also contains sialic acid synthesis capabilities. For example, the bacterium is provided with an exogenous UDP-GlcNAc 2-differentiase (e.g., neuC of Campylobacter jejuni (GenBank AAK91727.1; GL15193223) or an equivalent (e.g., neuC of Escherichia coli S88 (GenBank YP_002392936.1; GI:218560023), a Neu5Ac synthase (e.g., neuB of Campylobacter jejuni (GenBank AAK91726.1; GI:15193222)) or an equivalent (e.g., Flavobacterium limnosediminis sialic acid synthase, GenBank GL559220424) and / or a CMP-Neu5Ac synthase (e.g., neuA of Campylobacter jejuni (GenBank AAK91728.1; GI:15193224) or an equivalent (e.g., Vibrio brasiliensis CMP sialic acid synthase, GenBank GI:493937153) to comprise sialic acid synthesis capability.

[0062] It is known in the art to produce neutral N-acetylglucosamine containing HMOs in engineered bacteria and yeast (see, eg, Gebus C et al., (2012) Carbohydrate Research 363 83-90; US 10,519,475).

[0063] For producing HMOs containing N-acetylglucosamine, such as lacto-N-triose 2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP-I), lacto-N-fucopentaose II (LNFP-II), lacto-N-fucopentaose III (LNFP-III), lacto-N-fucopentaose V (LNFP-V), lacto-N-difucohexaose I (LDFH-I), lacto-N-difucohexaose II (LDFH-II) and lacto-N-neodifucohexaose II (LNDFH-III), as described above, the bacteria contain functional lacY and dysfunctional lacZ genes, and are engineered to contain an exogenous UDP-GlcNAc:Galα / β-Rβ-3-N-acetylglucosaminyltransferase gene or a functional variant or fragment thereof. Such exogenous UDP-GlcNAc:Galα / β-Rβ-3-N-acetylglucosaminyltransferase genes can be obtained from any of a variety of sources (see Table 1), for example, the lgtA gene described in N. meningitidis (Genbank protein accession number AAF42258.1) or N. gonorrhoeae (Genbank protein accession number ACF31229.1). Alternatively, additional exogenous glycosyltransferase genes can be co-expressed in bacteria containing exogenous UDP-GlcNAc:Galα / β-Rβ-3-N-acetylglucosaminyltransferase. For example, a β-1,4-galactosyltransferase (Gal4T) gene is co-expressed with a UDP-GlcNAc:Galα / β-Rβ-3-N-acetylglucosaminyltransferase gene. Such an exogenous β-1,4-galactosyltransferase gene can be obtained from any of a variety of sources, such as the described lgtB gene from Neisseria meningitidis (N. meningitidis) (Genbank protein accession number AAF42257.1) or the HP0826 / galT gene from Helicobacter pylori (H. pylori) (Genbank protein accession number NP_207619.1).Optionally, the additional exogenous glycosyltransferase gene co-expressed in the bacterium comprising the exogenous UDP-GlcNAc:Galα / β-Rβ-3-N-acetylglucosaminyltransferase (Gal3T) gene is a P1,3-galactosyltransferase gene, for example, the described wbgO gene from Escherichia coli 055:H7 (Genbank protein accession number WP_000582563.1) or the jhp0563 gene from Helicobacter pylori (Genbank protein accession number AEZ55696.1), or the cpslBJ gene from Streptococcus agalactiae Ib OI2 type (Genbank protein accession number AB050723). Functional variants and fragments of any of the above enzymes are also included in the present invention.

[0064] N-acetylglucosaminyltransferase gene and / or galactosyltransferase gene are also operably connected to Pglp and expressed from the corresponding genome integration box. In one embodiment, the genome integrated gene is a gene encoding galactosyltransferase, such as the HP0826 gene encoding the Helicobacter pylori GalT enzyme (Genbank protein accession number NP_207619.1); in another embodiment, the genome integrated gene is a gene encoding β-1,3-N-acetylglucosaminyltransferase, such as the lgtA gene from Neisseria meningitidis (Genbank protein accession number AAF42258.1). In these embodiments, the second gene, i.e., the gene encoding β-1,3-N-acetylglucosaminyltransferase or galactosyltransferase, can be expressed from a genome integration box or a plasmid vector box, accordingly. The second gene can be selectively expressed under the control of the glp promoter or under the control of any other promoter (e.g., Plac) suitable for the expression system.

[0065] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Singleton et al. (1994) Dictionary of Microbiology and Molecular Biology, Second Edition, John Wiley & Sons (New York), provides a general dictionary of many of the terms used in the present invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. Most of the nomenclature and general laboratory procedures required in this application can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (2012); Wilson K. and Walker J., Principles and Techniques of Biochemistry and Molecular Biology (2010), Cambridge University Press; or in Maniatise et al., Molecular Cloning A laboratory Manual, Cold Spring Harbor Laboratory (2012); or in Ausubel et al., Current protocols in molecular biology, John Wiley and Sohns (2010). These manuals are hereinafter referred to as "Sambrook et al.", "Wilson & Walker," "Maniatise et al.", "Ausubel et al.", respectively.

[0066] A second aspect of the invention relates to a method for producing one or more HMOs, the method comprising the steps of:

[0067] (i) providing a genetically modified cell capable of producing HMO, wherein the cell comprises a recombinant nucleic acid encoding a protein of SEQ ID NO: 1 or a functional homologue thereof, the amino acid sequence of the functional homologue having at least 80% identity, preferably at least 85% identity, more preferably at least 90% identity to SEQ ID NO: 1;

[0068] (ii) culturing the cell of (i) in a suitable cell culture medium to express the recombinant nucleic acid;

[0069] (iii) harvesting the one or more HMOs produced in step (ii).

[0070] According to the present invention, the term "culturing" (or "cultivating" or "cultivation" also referred to as "fermentation") relates to the propagation of bacterial expression cells in a controlled bioreactor according to methods known in the art.

[0071] In order to produce one or more HMOs, the HMO-producing bacteria described herein are cultured in the presence of a suitable carbon source (e.g., glucose, glycerol, lactose, etc.) according to procedures known in the art, and the produced HMOs are harvested from the culture medium and the microbial biomass formed during the culture process. Thereafter, the HMOs are purified according to procedures known in the art (e.g., as described in WO2015188834, WO2017182965, or WO2017152918), and the purified HMOs are used as nutraceuticals, drugs, or any other purpose, such as for research. The manufacture of HMOs is generally accomplished by mass cultivation. The terms "manufacturing" and "manufacturing scale" in the meaning of the present invention define fermentation with a minimum volume of 5 L of culture broth. Typically, a "manufacturing scale" process is defined as being able to process a large number of preparations containing one or more target HMOs and produce a target protein mass that meets the needs of clinical trials and market supply, for example, for therapeutic compounds or compositions. In addition to the large capacity, in contrast to simple laboratory-scale methods such as shake flask cultivation, manufacturing-scale methods are characterized by the use of technological systems of bioreactors (fermenters) equipped with stirring, aeration, nutrient feeding, monitoring and control of process parameters (pH, temperature, dissolved oxygen tension, back pressure, etc.). To a large extent, the behavior of the expression system in laboratory-scale methods, such as shake flasks, bench-top bioreactors or deep-well formats described in the present examples, does allow to predict the behavior of this system in the complex environment of a bioreactor.

[0072] There are no restrictions as to the suitable medium used in the fermentation process. The medium may be semi-defined, i.e. containing complex medium compounds (e.g. yeast extract, soy peptone, tyrosine amino acids, etc.), or chemically defined, not containing any complex compounds.

[0073] The term "one or more HMOs" means that the HMO producing cell can produce a single HMO structure (a first HMO) or multiple HMO structures (a second, third, etc. HMO). In some embodiments, a host cell that produces a single HMO may be preferred, and in other preferred embodiments, a host cell that produces multiple HMO structures may be preferred. Non-limiting examples of host cells that produce a single HMO structure are 3'-SL, 6'-SL or LNT-2 producing cells. Non-limiting examples of host cells that can produce multiple HMO structures may be FSL, LNT, LNnT, LNFP I, LNFP II, LNFP III, LNFP IV, LNFP V, pLNnH, pLNH-II producing cells.

[0074] The term "harvesting" in the context of the present invention relates to the collection of the produced HMOs after the fermentation is terminated. In different embodiments, it may include collecting the HMOs included in the biomass (i.e., host cells) and the culture medium, i.e., before / without separation of the fermentation broth from the biomass. In other embodiments, the produced HMOs may be collected separately from the biomass and the fermentation broth, i.e., after separation of the biomass from the culture medium (i.e., the fermentation broth). The cells may be separated from the culture medium using any method well known to those skilled in the art, such as any suitable type of centrifugation or filtration. The separation of cells from the culture medium may be performed immediately after the fermentation broth is harvested, or at a later stage after the fermentation broth has been stored under appropriate conditions. Recovering the produced HMOs from the remaining biomass (or total fermentation) includes extracting the HMOs from the biomass (i.e., producing cells). It may be accomplished by any suitable method in the art, such as by ultrasound, boiling, homogenization, enzymatic hydrolysis using lysozyme, or freezing and grinding.

[0075] After recovery from the fermentation, the HMOs can be used for further processing and purification.

[0076] HMOs produced by fermentation may be purified using appropriate procedures described in WO2016095924, WO2015188834, WO2017152918, WO2017182965, US20190119314 (all incorporated by reference).

[0077] In some embodiments of the invention, a host cell can produce multiple HMOs, one of which is a "product" HMO, and some / all other HMOs are "byproduct" HMOs. Typically, a byproduct HMO is a product of a major HMO precursor or further modification of a major HMO. In some embodiments, it may be desirable to produce a large amount of a product HMO and a small amount of a byproduct HMO. The cells and methods for HMO production described herein allow for the controlled production of an HMO product with a defined HMO distribution, for example, in one embodiment, a mixture of HMOs is produced in which the product HMO is the main HMO compared to the other HMOs (i.e., byproduct HMOs) of the mixture, i.e., the product HMO is produced in an amount higher than the other byproduct HMOs; in other embodiments, cells producing the same mixture of HMOs can be regulated to produce one or more byproduct HMOs in greater amounts than the product HMO. For example, during the production of LNnT, a product HMO is produced, typically a large amount of pLNnH, i.e., a byproduct HMO. Using the genetically modified cells of the present invention, the level of pLNnH in the LNnT product can be significantly reduced.

[0078] Advantageously, the present invention provides a reduced ratio of byproducts to products and an increased overall yield of product (and / or total HMO). Thus, less byproduct formation is associated with product formation, which helps to increase product yield, improve the efficiency of the production and product recovery process, and provide a high-quality HMO manufacturing process.

[0079] In different preferred embodiments, different host cells can be selected to produce one or both of 3'-SL, 6'-SL, LNT-2, FSL, LNT, LNnT, DFL, FSL, LNT, LNnT, LNFP I, LNFP II, LNFP III, LNFP IV, LNFP V, pLNnH, pLNH-II as product or by-product HMO. In a preferred embodiment, the product is LNT-2 and the by-product is pLNnH. In another preferred embodiment, the product is LNnT and the by-product is pLNnH. In another preferred embodiment, the product is LNT and the by-product is pLNH-II. In another preferred embodiment, the product is LNT2 and the by-product is pLNH-II.

[0080] The present invention further relates to the use of a genetically modified cell and / or a nucleic acid construct according to the invention for producing one or more oligosaccharides, preferably one or more human milk oligosaccharides.

[0081] In one embodiment, the genetically modified cells and / or nucleic acid constructs according to the present invention are used to produce a specific HMO selected from 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose IV (LNFP IV) and lacto-N-fucopentaose V (LNFP V), p-lacto-N-neohexose (pLNnH) and p-lacto-neohexose II (pLNH-II).

[0082] In a preferred embodiment, the genetically modified cells and / or nucleic acid constructs according to the present invention are used to produce a specific HMO selected from lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose IV (LNFP IV), lacto-N-fucopentaose V (LNFP V), p-lacto-N-neohexose (pLNnH) and p-lacto-neohexose II (pLNH-II).

[0083] In another preferred embodiment, the genetically modified cells and / or nucleic acid constructs according to the invention are used to produce an HMO selected from the group consisting of lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and p-lacto-neohexaose II (pLNH-II).

[0084] In a particularly preferred embodiment, the genetically modified cells or nucleic acid constructs according to the invention are used for the production of a specific HMO selected from lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).

[0085] The present invention is further illustrated by the following non-limiting examples and embodiments.

[0086] Example

[0087] Materials and methods

[0088] Unless otherwise indicated, standard techniques, vectors, control sequence elements and other expression system elements known in the field of molecular biology can be used for nucleic acid manipulation, transcription and expression. Such standard techniques, vectors and elements can be found, for example: Ausubel et al. (author), Current Protocols in Molecular Biology (1995) (John Wiley & Sons); Sambrook, Fritsch, & Maniatis (author), Molecular Cloning (1989) (Cold Spring Harbor Laboratory Press, NY); Berger & Kimmel, Methods in Enzymology 152: Guide to Molecular Cloning Techniques (1987) (Academic Press); Bukhari et al. (author), DNA Insertion Elements, Plasmids and Episomes (1977) (Cold Spring Harbor Laboratory Press, NY); Miller, JH Experiments in molecular genetics (1972.) (Cold spring Harbor Laboratory Press, NY).

[0089] The embodiments described below are intended to illustrate the present invention, but are not intended to limit the present invention in any way.

[0090] strain

[0091] The bacterial strain MDO used was constructed from E. coli K-12 DH1. The genotype of E. coli K12 DH1 is: F - , gyrA96, recA1, relA1, endA1, thi-1, hsdR17, supE44. The strains used in this example are described in Table 2.

[0092] Table 2

[0093]

[0094] Culture medium

[0095] Luria Broth (LB) medium was prepared using LB Broth Powder, Millers (Fisher Scientific), and LB agar plates were prepared using LB Agar Powder, Millers (Fisher Scientific). Ampicillin (100 μg / mL) or any appropriate antibiotic and / or chloramphenicol (20 μg / mL) were added as appropriate.

[0096] The composition of the basal minimum medium is as follows: NaOH (1 g / L), KOH (2.5 g / L), KH2PO4 (7 g / L), NH4H2PO4 (7 g / L), citric acid (0.5 g / L), trace mineral solution (5 mL / L). The trace mineral stock solution contains: ZnSO4 * 7H2O0.82g / L, citric acid 20g / L, MnSO4 * H2O 0.98g / L, FeSO4 * 7H2O 3.925g / L, CuSO4 * 5H2O 0.2g / L. The pH value of the basic minimum medium was adjusted to 7.0 with 5NNaOH and autoclaved. Prior to inoculation, the basic minimum medium was provided with 1mM MgSO4, 4μg / mL thiamine, 0.5% of a given carbon source (glycerol (Carbosynth)), and isopropyl-β-D-thiogalactoside (IPTG) (0.2mM) was added when appropriate. Thiamine, antibiotics, and IPTG were sterilized by filtration. All percentage concentrations of glycerol are expressed as v / v, and all percentage concentrations of glucose are expressed as w / v.

[0097] M9 plates containing 2-deoxygalactose had the following composition: 15 g / L agar (Fisher Scientific), 2.26 g / L 5x M9 trace salts (Sigma-Aldrich), 2 mM MgSO4, 4 μg / mL thiamine, 0.2% glycerol, and 0.2% 2-deoxy-D-galactose (Carbosynth).

[0098] The composition of the MacConkey indicator plate is as follows: 40 g / L MacConkey agar base (BD Difco TM ) and a carbon source at a final concentration of 1%.

[0099] nourish

[0100] Unless otherwise stated, E. coli strains were propagated with agitation in Luria-Bertani (LB) medium containing 0.2% glucose at 37° C. Agar plates were incubated overnight at 37° C.

[0101] Chemically competent cells and transformation

[0102] At 37°C, E. coli was inoculated from the LB plate into 5 mL LB containing 0.2% glucose and shaken until OD600~0.4. 2 mL of culture was harvested by centrifugation at 13,000g for 25 seconds. The supernatant was removed and the cell pellet was resuspended in 600 μL cold TB solution (10 mM PIPES, 15 mM CaCl2, 250 mM KCl). The cells were incubated on ice for 20 minutes and then precipitated at 13,000g for 15 seconds. The supernatant was removed and the cell pellet was resuspended in 100 μL cold TB solution. 100 μL competent cells and 1-10 ng plasmid DNA were used for plasmid transformation. The cells and DNA were incubated on ice for 20 minutes and then heat-shocked at 42°C for 45 seconds. After incubation on ice for 2 min, 400 μL SOC (20 g / L tryptone, 5 g / L yeast extract, 0.5 g / L NaCl, 0.186 g / L KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) was added and the cell culture was incubated with shaking at 37°C for 1 h before plating on selective plates.

[0103] Plasmids were transformed into TOP10 chemically competent cells under conditions recommended by the supplier (ThermoFisher Scientific).

[0104] DNA Technology

[0105] Plasmid DNA was isolated from E. coli using the QIAprep Spin Miniprep Kit (Qiagen). Chromosomal DNA was isolated from E. coli using the QIAmp DNA Mini Kit (Qiagen). PCR products were purified using the QIAquick PCR Purification Kit (Qiagen). DreamTaq PCR Master Mix (Thermofisher), Phusion U hot start PCR master mix (Thermofisher), USER enzyme (New England Biolab) were used as recommended by the supplier. Primers were provided by Eurofins Genomics, Germany. PCR fragments and plasmids were sequenced by Eurofins Genomics. TMColony PCR was performed using DreamTaq PCR Master Mix in a thermal cycler (Bio-Rad).

[0106] Table 3: Oligonucleotides used to amplify plasmid backbone, promoter elements and target genes

[0107]

[0108] Table 4: Heterologous transporter genes tested for their ability to promote HMO production in microorganisms

[0109] Gene Gene source Accession Number Function yberC0001_9420 Yersinia bercovieri EEQ08298 MFS transporter

[0110] Table 5: Synthetic DNA elements for expressing YberC

[0111]

[0112]

[0113] Plasmid construction

[0114] The synthetic plasmid backbone comprises two I-SceI restriction endonuclease sites and a T1 transcription terminator sequence separated by two DNA fragments suitable for homologous recombination to the Escherichia coli genome. For example, the gal operon (required for homologous recombination in galK) and a T1 transcription terminator sequence (pUC57::gal) (GeneScript) are synthesized in a plasmid backbone. The DNA sequence dna used for homologous recombination in the gal operon covers the base pairs 3.628.621-3.628.720 and 3.627.572-3.627.671 in the complete genome of Escherichia coli K-12MG155 GenBank:ID:CP014225.1. Insertion by homologous recombination will cause 949 base pair deletions of galK and the galK-phenotype. In a similar manner, a backbone based on pUC57 (GeneScript) or any other suitable vector can be synthesized, which contains two I-SceI endonuclease sites and a T1 transcription terminator sequence separated by two DNA fragments for homologous recombination into the Escherichia coli genome. Standard techniques well known in the field of molecular biology are used to design primers and amplify specific DNA sequences of Escherichia coli K-12DH1 chromosomal DNA. These standard techniques, vectors and elements can be found in, for example: Ausubel et al. (write), Current Protocols in Molecular Biology (1995) (John Wiley & Sons); Sambrook, Fritsch and Maniatis (write), Molecular Cloning (1989) (New York Cold Spring Harbor Laboratory Press); Berger and Kimmel, Methods in Enzymology 152: Guide to Molecular Cloning Techniques (1987) (Academic Press); Bukhari et al. (write).

[0115] Chromosomal DNA obtained from E. coli DH1 was used to amplify a 300 bp DNA fragment containing the promoter PglpF using oligonucleotides O261 and O262, and a 195 bp DNA fragment containing Plac using oligonucleotides O68 and O113 (Table 3).

[0116] A 1182 bp DNA fragment containing a codon-optimized variant of the yberC0001_9420 gene from Yersinia bercovieri (Table 5) was synthesized by GeneScript. The yberC0001_9420 gene was amplified by PCR using oligonucleotides KABY721 and KABY722.

[0117] Purify all PCR fragments (plasmid backbone, promoter-containing elements and YberC gene), assemble plasmid backbone, promoter elements (PglpF or Plac) and DNA fragments containing YberC. Clone plasmids by standard USER cloning. Any standard DNA cloning technique can be used to clone in any appropriate plasmid. Transform the plasmid into TOP10 cells and select on LB plates containing 100 μg / mL ampicillin (or any suitable antibiotic) and 0.2% glucose. Purify the constructed plasmid and verify the promoter sequence and the 5′ end of the YberC gene by DNA sequencing (MWGEurofins Genomics). In this way, a gene cassette containing any promoter connected to the YberC gene is constructed.

[0118] Table 6: Examples of helper and donor plasmids used for strain construction

[0119] Plasmids Related genotypes Marker Gene PcbS Para-I-SceI-λRed, p15A ori, cam* cam pUC57 pMB1,bla bla pUC57::gal pUC57::galTK' / T1-galKM' bla

[0120] The DNA sequence of the heterologous gene encoding the target transporter or glycosyltransferase was codon optimized and synthesized by GenScript. The target gene (Table 3) encoding the transporter YberC (Table 4) was amplified by PCR using appropriate primers covering the gene start codon ATG and stop codon TAA. In order to construct a donor plasmid containing any target heterologous gene, the purified PCR fragments of the relevant plasmid backbone, promoter element and target gene were combined using standard USER cloning. Any standard DNA cloning technique can be used to clone in an appropriate plasmid. After cloning, the DNA was transformed into TOP10 cells and selected on LB plates containing 100 μg / mL ampicillin (or 50 mg / mL kanamycin, depending on the backbone used) and 0.2% glucose. The constructed plasmid was purified and the promoter sequence and the 5' end of the target gene were verified by DNA sequencing (MWG Eurofins Genomics).

[0121] Construction of strains

[0122] The bacterial strain MDO used was constructed from Escherichia coli K-12DH1. The genotype of Escherichia coli K-12DH1 is: F - , gyrA96, recA1, relA1, endA1, thi-1, hsdR17, supE44. In addition to the E. coli K-12DH1 genotype, MDO had the following modifications: lacZ: 1.5 kbp deletion, lacA: 0.5 kbp deletion, nanKETA: 3.3 kbp deletion, melA: 0.9 kbp deletion, wcaJ: 0.5 kbp deletion, mdoH: 0.5 kbp deletion, and Plac promoter was inserted upstream of the gmd gene.

[0123] As described by Herring et al. (Herring, CD, Glasner, JD and Blattner, FR (2003). Gene (311). 153-163), an expression cassette containing a promoter connected to the yberC0001_9420 gene and a T1 transcription terminator sequence was inserted by Gene Gorging, and examples of helper plasmids and donor plasmids used to construct the strains described in this application are provided in Table 6. Briefly, the donor plasmid and helper plasmid were co-transformed into MDO and selected on LB plates containing 0.2% glucose, ampicillin (100 μg / mL) or kanamycin (50 mg / mL) and chloramphenicol (20 μg / mL). Single colonies were inoculated in 1 mL LB containing chloramphenicol (20 μg / mL) and 10 μL of 20% L-arabinose and cultured at 37°C with shaking for 7 to 8 hours. In order to integrate into the galK site of Escherichia coli, the cells were then inoculated on M9-DOG plates and cultured for 48 hours at 37°C. The single colonies formed on the MM-DOG plates were streaked again on LB plates containing 0.2% glucose and cultured for 24 hours at 37°C. The colonies that showed white on MacConkey galactose agar plates and were sensitive to ampicillin and chloramphenicol were expected to have lost the donor and helper plasmids and included insertion in the galK site. Primers O48 (SEQ ID NO:13) and O49 (SEQ ID NO:14) were used to identify the insertion of the galK site by colony PCR, and the inserted DNA was verified by sequencing (Eurofins Genomics, Germany).

[0124] The genetic cassettes are inserted into other sites of the E. coli chromosomal DNA in a similar manner using different selectable marker genes.

[0125] Deep hole test (DWA)

[0126] DWA was performed as originally described by Lv et al. (Bioprocess Biosyst Eng (2016) 39: 1737-1747) and optimized for the purposes of the present invention.

[0127] More specifically, the strain disclosed in the example was screened in 24 deep well plates using a 4-day scheme. Within the first 24 hours, the cells grew to a high density, and within the next 72 hours, the cells were transferred to a culture medium that could induce gene expression and product formation. Specifically, on the first day, a fresh inoculum was prepared using a basic minimal culture medium supplemented with magnesium sulfate, thiamine and glucose. After the prepared culture was cultured at 34°C under shaking at 700rpm for 24 hours, the cells were transferred to a new basic minimal culture medium (2ml) supplemented with magnesium sulfate and thiamine, to which an initial dose of 20% glucose solution (1μL) and 10% lactose solution (0.1ml) were added, and then 50% sucrose solution was provided to the cells as a carbon source. After inoculation of the new culture medium, the cells were shaken at 700rpm for 72 hours at 28°C. After denaturation and subsequent centrifugation, the supernatant was analyzed by HPLC.

[0128] For analysis of total samples, cell lysates prepared by boiling were pelleted by centrifugation at 4,700 rpm for 10 minutes. HMO concentrations in the supernatant were determined by HPLC or HPAC methods.

[0129] result

[0130] Example 1. Engineering E. coli using the yberC0001_9420 gene for the production of LNT-2

[0131] E. coli K-12 (DH1) MDO strains can be manipulated to express a heterologous gene of interest. For example, strain MP3941 is a LNT-2 producing strain that optimally overexpresses a β-1,3-N-acetylglucosaminyltransferase gene selected from the non-limiting examples in Table 1, such as lgtA.

[0132] Total sample analysis ( Figure 3 ) showed that when an expression cassette containing a promoter element (PglpF) linked to the yberC0001_9420 gene was integrated into the chromosomal DNA of strain MP3941 in a single copy to generate strain MP3940, the LNT-2 titer could be significantly increased (Table 2). Interestingly, the LNT-2 extracellular fraction of strain MP3940 was also much larger than that of strain MP3941, a fact also reflected in the fact that the level of trisaccharide detected in the precipitate fraction of yberC0001_9420-expressing strain MP3940 was lower than that in the non-transporter-expressing strain MP3941 ( Figure 1 ).

[0133] Example 2. Engineering E. coli using the yberC0001_9420 gene for producing LNnT

[0134] E. coli K-12 (DH1) MDO strains can be manipulated to express heterologous genes of interest. For example, strain MP4436 is a LNnT producing strain that overexpresses β-1,3-N-acetylglucosaminyltransferase genes and β-1,3-galactosyltransferase genes selected from the non-limiting examples of Table 1, such as lgtA and galT, at optimal levels.

[0135] As shown by HPLC analysis of total samples, the expression cassette containing the promoter element Plac linked to the yberC0001_9420 gene was inserted in a single copy into the chromosomal DNA of strain MP4436 to generate strain MP3863 (Table 2), resulting in i) a decrease in total LNnT titer, ii) a slightly higher total LNT-2 concentration, and iii) a significant decrease in total pLNnH formation ( Figure 2 ).

[0136] Although total LNnT titers were not increased in the yberC0001_9420 expressing strain MP3863 compared to the reference strain MP4436, a significant increase in the extracellular LNnT fraction was evident from analysis of supernatant samples. Similar observations were made for LNT-2 concentrations in the culture medium of MP3863 cultures, where the LNT-2 fraction was increased at least 2-fold compared to the corresponding fraction of strain MP4436 ( Figure 2 ). The latter observation could easily explain the lower LNnT titers obtained for strain MP3863 compared to strain MP4436, since the precursor sugar molecule LNT-2 is more efficiently transported out of the cells in the presence of the YberC0001_9420 transporter. Therefore, LNnT and LNT-2 concentrations were significantly reduced in the precipitate samples of the yberC0001_9420 expressing strain MP3863. As mentioned above, pLNnH formation was greatly reduced in strain MP3863 compared to strain MP4436. Interestingly, pLNnH seemed to be found only in the cell precipitate of strain MP3863, so without being bound by any scientific theory, it does not seem to be a substrate for the YberC0001_9420 transporter ( Figure 2 ).

[0137] Example 3. Engineering E. coli using the yberC0001_9420 gene for LNT production

[0138] E. coli K-12 (DH1) MDO strains can be manipulated to express heterologous genes of interest. For example, strain MP4473 is a LNT-producing strain that expresses a β-1,3-N-acetylglucosaminyltransferase gene and a β-1,3-galactosyltransferase gene selected from the non-limiting examples of Table 1, such as lgtA and galT, at optimal levels.

[0139] Insertion of an expression cassette containing the promoter element Plac linked to the yberC0001_9420 gene in a single copy into the chromosomal DNA of strain MP4473 to generate strain MP4462 (Table 2) had a significant effect on the total HMO titer and HMO distribution between the cell culture supernatant and pellet fractions ( Figure 3 ).

[0140] As shown in the analysis of total samples, Plac-driven expression of the yberC0001_9420 gene had a significant positive effect on total LNT titers, accompanied by a more than 2-fold increase in total LNT-2 titers and a significant reduction in total pLNH-II formation.

[0141] The significant impact of the introduction of the yberC0001_9420 gene under the control of a moderately strong expression element (e.g., Plac) in the genetic background of an LNT-producing strain with optimal glycosyltransferase expression was further emphasized by observing that the concentration of LNT in the supernatant fraction of the culture of strain MP4462 was greatly increased ( 1.1 % vs. 1.3 % in the culture medium of MP4473). Figure 3 ). Consistent with the higher total LNT-2 titers observed in the transporter-expressing strain MP4462 compared to the reference strain MP4473, the LNT-2 concentration in the supernatant samples of the former strain was at least twice as high as that of the latter strain. Thus, the concentration of LNT (but not LNT-2) in the precipitate of strain MP4462 expressing yberC0001_9420 was significantly reduced. As described above, pLNH-II formation was greatly reduced in strain MP4462. Interestingly, pLNH-II appears to be found only in the cell precipitate of strain MP4462, so without being bound by any scientific theory, it does not appear to be a substrate for the YberC0001_9420 transporter ( Figure 3 ). Sequence Listing <110> Glycom A / S <120> HMO production <130> P2940WO00 <150> DK202000088 <151> 2020-01-23 <160> 17 <170> BiSSAP 1.3.6 <210> 1 <211> 393 <212> PRT <213> Yersinia bercovieri <220> <223> YberC_EEQ08298.1 \ optimized translation: <400> 1 Met Lys Ser Ala Leu Thr Phe Ser Arg Arg Ile Asn Pro Val Phe Leu 1 5 10 15 Ala Phe Phe Val Val Ala Phe Leu Ser Gly Ile Ala Gly Ala Leu Gln 20 25 30 Ala Pro Thr Leu Ser Leu Phe Leu Ser Thr Glu Val Lys Val Arg Pro 35 40 45 Leu Trp Val Gly Leu Phe Tyr Thr Val Asn Ala Ile Ala Gly Ile Thr 50 55 60 Val Ser Phe Ile Leu Ala Lys Arg Ser Asp Ser Arg Gly Asp Arg Arg 65 70 75 80 Lys Leu Ile Met Val Cys Tyr Leu Met Ala Val Gly Asn Cys Leu Leu 85 90 95 Phe Ala Phe Asn Arg Asp Tyr Leu Thr Leu Ile Thr Ala Gly Val Leu 100 105 110 Leu Ala Ser Val Ala Asn Thr Ala Met Pro Gln Ile Phe Ala Leu Ala 115 120 125 Arg Glu Tyr Ala Asp Ser Ser Ala Arg Glu Val Val Met Phe Ser Ser 130 135 140 Ile Met Arg Ala Gln Leu Ser Leu Ala Trp Val Ile Gly Pro Pro Leu 145 150 155 160 Ser Phe Met Leu Ala Leu Asn Tyr Gly Phe Thr Leu Met Phe Ser Ile 165 170 175 Ala Ala Gly Ile Phe Val Leu Ser Ala Leu Val Val Trp Phe Ile Leu 180 185 190 Pro Ser Val Pro Arg Ala Glu Pro Val Val Asp Ala Pro Val Val Val 195 200 205 Gln Gly Ser Leu Phe Ala Asp Lys Asn Val Leu Leu Leu Phe Ile Ala 210 215 220 Ser Met Leu Met Trp Thr Cys Asn Thr Met Tyr Ile Ile Asp Met Pro 225 230 235 240 Leu Tyr Ile Thr Ala Ser Leu Gly Leu Pro Glu Arg Leu Ala Gly Leu 245 250 255 Leu Met Gly Thr Ala Ala Gly Leu Glu Ile Pro Ile Met Leu Leu Ala 260 265 270 Gly Tyr Ser Val Arg Tyr Phe Gly Lys Arg Lys Ile Met Leu Phe Ala 275 280 285 Val Leu Ala Gly Val Leu Phe Tyr Thr Gly Leu Val Leu Phe Lys Phe 290 295 300 Lys Thr Ala Leu Met Leu Leu Gln Ile Phe Asn Ala Ile Phe Ile Gly 305 310 315 320 Ile Val Ala Gly Ile Gly Met Leu Tyr Phe Gln Asp Leu Met Pro Gly 325 330 335 Arg Ala Gly Ala Ala Thr Thr Leu Phe Thr Asn Ser Ile Ser Thr Gly 340 345 350 Val Ile Leu Ala Gly Val Leu Gln Gly Gly Leu Thr Glu Thr Trp Gly 355 360 365 His Asp Ser Val Tyr Val Met Ala Met Val Leu Ser Ile Leu Ala Leu 370 375 380 Ile Ile Cys Ala Arg Val Arg Glu Ala 385 390 <210> 2 <211> 1182 <212> DNA <213> Yersinia bercovieri <220> <223> YberC nucleotide sequence <400> 2 atgaagagcg cgctgacctt tagccgtcgt atcaatccgg tgtttctggc gtttttcgtg 60 gtggcgttcc tgagcggtat tgcgggtgcg ctgcaggcgc cgaccctgag cctgtttctg 120 agcaccgagg ttaaagtgcg tccgctgtgg gttggcctgt tttacaccgt gaacgcgatt 180 gcgggtatca ccgttagctt cattctggcg aagcgtagcg acagccgtgg cgatcgtcgt 240 aaactgatca tggtttgcta cctgatggcg gtgggtaact gcctgctgtt cgcgtttaac 300 cgtgactatc tgaccctgat taccgcgggc gttctgctgg cgagcgtggc gaacaccgcg 360 atgccgcaga ttttcgcgct ggcgcgtgag tatgcggata gcagcgcgcg tgaagtggtt 420 atgttcagca gcattatgcg tgcgcaactg agcctggcgt gggtgattgg tccgccgctg 480 agcttcatgc tggcgctgaa ctatggcttc accctgatgt ttagcattgc ggcgggtatc 540 tttgttctga gcgcgctggt tgtgtggttc attctgccga gcgtgccgcg tgcggaaccg 600 gtggttgacg cgccggtggt tgtgcagggc agcctgtttg cggataaaaa cgttctgctg 660 ctgttcattg cgagcatgct gatgtggacc tgcaacacca tgtacatcat tgacatgccg 720 ctgtatatca ccgcgagcct gggtctgccg gagcgtctgg cgggtctgct gatgggcacc 780 gcggcgggtc tggaaatccc gattatgctg ctggcgggct acagcgtgcg ttatttcggc 840 aagcgtaaaa tcatgctgtt tgcggttctg gcgggcgtgc tgttctacac cggtctggtt 900 ctgttcaagt ttaaaaccgc gctgatgctg ctgcagattt tcaacgcgat ctttattggc 960 atcgtggcgg gtatcggcat gctgtatttt caagacctga tgccgggtcg tgcgggtgcg 1020 gcgaccaccc tgttcaccaa cagcattagc accggcgtta tcctggcggg tgtgctgcaa 1080 ggtggcctga ccgaaacctg gggtcacgat agcgtttatg tgatggcgat ggttctgagc 1140 attctggcgc tgattatctg cgcgcgtgtg cgtgaggcgt aa 1182 <210> 3 <211> 300 <212> DNA <213> Artificial sequence <220> <223> PglpF expression element <300> <310> WO2019123324 <311> 19.12.2018 <312> 27.06.2019 <400> 3 gcggcacgcc ttgcagatta cggtttgcca cacttttcat ccttctcctg gtgacataat 60 ccacatcaat cgaaaatgtt aataaatttg ttgcgcgaat gatctaacaa acatgcatca 120 tgtacaatca gatggaataa atggcgcgat aacgctcatt ttatgacgag gcacacacat 180 tttaagttcg atatttctcg tttttgctcg ttaacgataa gtttacagca tgcctacaag 240 catcgtggag gtccgtgact ttcacgcata caacaaacat taaccaagga ggaaacagct 300 <210> 4 <211> 195 <212> DNA <213> Artificial sequence <220> <223> Plac expression element <300> <310> WO2019123324 <311> 19.12.2018 <312> 27.06.2019 <400> 4 atgcgcaaat tgtgagttag ctcactcatt aggcacccca ggctttacac tttatgcttc 60 cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatg 120 accatgatta cgccaagcgc gcaattaacc ctcactaaag ggaacaaaag ctgggtacct 180 aaggaggaaa cagct 195 <210> 5 <211> 34 <212> DNA <213> Artificial sequence <220> <223> Primer O40 backbone.for <220> <221> misc_RNA <222> 9 <400> 5 attaacccuc caggcatcaa ataaaacgaa aggc 34 <210> 6 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Plac.for <400> 6 atgcgcaaau tgtgagttag ctcactcatt ag 32 <210> 7 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primer O79 backbone.rev <220> <221> misc_RNA <222> 10 <400> 7 atttgcgcau caccaatcaa attcacgcgg cc 32 <210> 8 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Plac.rev <400> 8 agctgttucc tccttaggta cccagctttt gttccc 36 <210> 9 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primers O261, PglpF.for <220> <221> misc_RNA <222> 10 <400> 9 atgcgcaaau gcggcacgcc ttgcagatta cg 32 <210> 10 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Primers O262, PglpF.rev <220> <221> misc_RNA <222> 8 <400> 10 agctgttucc tccttggtta atgtttgttg tatgcg 36 <210> 11 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primers KABY721, yberC0001_9420.for <220> <221> misc_RNA <222> 8 <400> 11 aaacagcuat gaagagcgcg ctgaccttta gc 32 <210> 12 <211> 29 <212> DNA <213> Artificial sequence <220> <223> Primers KABY722, yberC0001_9420.rev <220> <221> misc_RNA <222> 9 <400> 12 agggttaaut tacgcctcac gcacacgcg 29 <210> 13 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Primer O48, galK.for <400> 13 cccagcgaga cctgaccgca gaac 24 <210> 14 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Primer O49, glaK.rev <400> 14 ccccagtcca tcagcgtgac tacc 24 <210> 15 <211> 203 <212> DNA <213> Artificial sequence <220> <223> Promoter sequence Pmg1B_70UTR <400> 15 tgcgtcgcca ttctgtcgca acacgccaga atgcggcggc gatcactaac tcaacaaatc 60 aggcgatgta accgctttca atctgtgagt gatttcacag tatcttaaca atgtgatagc 120 tatgattgca ccgtgcctac aagcatcgtg gaggtccgtg actttcacgc atacaacaaa 180 cattaaccaa ggaggaaaca gct 203 <210> 16 <211> 203 <212> DNA <213> Artificial sequence <220> <223> Promoter sequence Pmg1B_70UTR_SD4 <400> 16 tgcgtcgcca ttctgtcgca acacgccaga atgcggcggc gatcactaac tcaacaaatc 60 aggcgatgta accgctttca atctgtgagt gatttcacag tatcttaaca atgtgatagc 120 tatgattgca ccgtgcctac aagcatcgtg gaggtccgtg actttcacgc atacaacaaa 180 cattaaccaa ctaggaaaca gct 203 <210> 17 <211> 291 <212> DNA <213> Artificial sequence <220> <223> Promoter sequence PgatY_70UTR <400> 17 cggcaaccta tgcctgatgc gacgctgaag cgtcttatca tgcctacata gcactgccac 60 gtatgtttac accgcatccg gcataaaaac acgcgcactt tgctacggct tccctatcgg 120 gaggccgttt ttttgccttt cactcctcga ataattttca tattgtcgtt tttgtgatcg 180 ttatctcgat atttaaaaac aaataatttc attatatttt gtgcctacaa gcatcgtgga 240 ggtccgtgac tttcacgcat acaacaaaca ttaaccaagg aggaaacagc t 291

Claims

1. A genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs) selected from 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) or lacto-N-fucopentaose I (LNFP I), wherein the cell comprises a. a recombinant nucleic acid encoding the protein of SEQ ID NO: 1, and b. One or more enzymes having glycosyltransferase activity selected from enzymes having the following activities i) α-2,3-sialyltransferase or α-2,6-sialyltransferase; or ii) β-1,3-N-acetylglucosaminyltransferase; or iii) β-1,3-N-acetylglucosaminyltransferase and β-1,3-galactosyltransferase; or iv) β-1,3-N-acetylglucosaminyltransferase and β-1,4-galactosyltransferase; or v) β-1,3-N-acetylglucosaminyltransferase and β-1,3-galactosyltransferase and α-1,2-fucosyltransferase.

2. The genetically modified cell according to claim 1, wherein the oligosaccharide is selected from lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT) or lacto-N-neotetraose (LNnT).

3. The genetically modified cell of any one of the preceding claims, wherein the genetically modified cell is Escherichia coli.

4. The genetically modified cell of claim 1, wherein the cell further comprises a recombinant DNA sequence comprising a regulatory element for regulating expression of the recombinant nucleic acid.

5. The genetically modified cell according to claim 4, wherein the regulatory element for regulating the expression of the recombinant nucleic acid is a promoter element.

6. The genetically modified cell according to claim 5, wherein the promoter element is the lac promoter Plac or the glp promoter PglpF.

7. A method for producing an oligosaccharide selected from 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) or lacto-N-fucopentaose I (LNFP I), the method The following steps are involved: (i) providing a genetically modified cell according to any one of claims 1 to 6; (ii) culturing the cell according to (i) in a suitable cell culture medium to express the recombinant nucleic acid; and (iii) harvesting the one or more HMOs produced in step (ii).

8. Use of the genetically modified cell according to any one of claims 1 to 6 for producing a specific HMO, wherein the specific HMO is selected from 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) or lacto-N-fucopentaose 1 (LNFP 1).

9. Use of the genetically modified cell according to any one of claims 1 to 6 for producing a specific HMO selected from the group consisting of lacto-N-triose-2 (LNT-2), lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).

Citation Information

Patent Citations

  • Biosynthesis of compounds in yeast

    US10519475B1

  • Separation of oligosaccharides from fermentation broth

    US20190119314A1

  • Increasing export of 2? fucosyllactose from microbial cells through the expression of a heterologous nucleic acid

    US20190323052A1

  • Increasing activity of 2? fucosyllactose transporters endogenous to microbial cells

    US20190323053A1

  • HMO synthesis

    WO2010142305A1